Nuvation Bio (NUVB) Could Be 48% Undervalued As Safusidenib Data Strengthens Its Case

Nuvation Bio (NUVB) is in focus after updated long term Phase 2 and Phase 3 data for safusidenib in grade 2 IDH1-mutant glioma showed strong response rates and a consistent safety profile.

See our latest analysis for Nuvation Bio.

The positive safusidenib data arrives as Nuvation Bio’s share price has climbed in the short term, with a 1-month share price return of 15.65% and a 3-month gain of 25.59%. However, the year-to-date share price is still down 25.06%, while the 1-year total shareholder return is about 2.7x, signaling that recent momentum has built on an already strong recovery.

If this glioma update has you rethinking where cancer drug development might create future opportunities, it can be useful to scan a wider set of oncology focused ideas through 39 healthcare AI stocks

After Nuvation Bio’s sharp rebound and the latest safusidenib data, the stock still trades well below the average analyst value estimates. This raises the question of where a reasonable view of fair value sits within that gap.

Most Popular Narrative: 47.9% Undervalued

Nuvation Bio’s most followed valuation narrative puts fair value at $12.33 a share, compared with the latest close of $6.43, and builds that gap around two oncology assets that are expected to underpin long term revenue growth.

Advancement of safusidenib into a pivotal Phase III high grade IDH1 mutant glioma maintenance study, targeting a population underserved by existing therapies, could position the company to tap into a durable brain tumor market and add a second meaningful revenue pillar that has the potential to scale earnings beyond IBTROZI.

Read the complete narrative.

Want to see how this glioma thesis and the IBTROZI roll out are built into revenue growth, margins and a premium earnings multiple over time? The narrative breaks that valuation story into specific assumptions on future sales, profitability and the P/E level required to justify a fair value almost double today’s share price.

Result: Fair Value of $12.33 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Nuvation Bio story still faces clinical and commercial risk, including timing around the safusidenib Phase 3 readout and competition for IBTROZI in ROS1+ lung cancer.

Find out about the key risks to this Nuvation Bio narrative.

Another View on Nuvation Bio: Multiples Point to Rich Pricing

The DCF based fair value for Nuvation Bio paints a discounted picture, but the simple P/S check tells a different story. NUVB trades at a P/S of 15.7x versus 6.7x for the US pharmaceuticals industry, 6.4x for peers and a fair ratio of 15x, which suggests less room for error if growth or margins disappoint.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this combination of optimism around Nuvation Bio and concern about its risks has you thinking, take a closer look at the full picture yourself and move quickly to form your own view with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Nuvation Bio?

If Nuvation Bio has sharpened your thinking, do not stop here. Broaden your watchlist with a few focused stock ideas that fit clear, simple criteria.

• Start with potential mispricing by scanning companies flagged as 50 high quality undervalued stocks to see where fundamentals and price may not fully line up.
• Strengthen your income stream by reviewing businesses in the 9 dividend fortresses that pair higher yields with an emphasis on staying power.
• Round out your shortlist with resilient options from the 81 resilient stocks with low risk scores so sharp drawdowns in weaker stocks do not catch you off guard.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com